Shares of CSL Fall After Canada Unit Signs LOI With Pharmaceutical Alliance
MT Newswires Live
Oct 07
Shares of CSL (ASX:CSL) fell 1% in recent Tuesday trade after the company said in a late Monday statement that its unit, CSL Behring Canada, signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Hemgenix, the unit's gene therapy to treat adults with the life-threatening rare disease Hemophilia B.
Under the LOI, provinces and territories outside of Quebec will list Hemgenix as part of their formularies, the statement said.
CSL Behring is in talks with the province of Quebec to secure public reimbursement for Hemgenix, the statement added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.